corp_html/html/RnD-Profile.htm

<p><b>Researching the Fight Against Infection</b></p>
<p>PLIVA is working on becoming a leader in anti-infectives research. As such, 
  current in-house activities are focused predominantly on anti-bacterials; the 
  largest segment of anti-infectives, and in this area, PLIVA has a long tradition 
  and much expertise.</p>
<p>With its internationally acknowledged insight into macrolide chemistry, as 
  evidenced by its discovery of Azithromycin, PLIVA has entered into a strategic 
  co-operation with GlaxoWellcome (with the merger of SmithKline and Glaxo a novel 
  Joint Operating Committee is currently being set up) to identify a novel macrolide 
  antibiotic for world-wide development and marketing. The goal of this venture 
  is to identify a macrolide with improved efficacy, particularly against resistant 
  strains of bacteria. The program is currently keeping pace with its ambitious 
  plans and efforts are being focused on fine-tuning the derivation process in 
  order to enter the development phase within the next year.</p>
<p align="center"><img src="p/OKrnd_ljudi_7.jpg" width="300" height="202"></p>
<p>The goal of a second program within this area is to find a novel anti-bacterial 
  compound class showing no cross-resistance with current antibiotics. In cooperation 
  with Althexis, Boston, USA, a company with leading expertise in structure-based 
  drug design and crystallography, researchers from both companies have identified 
  two novel scaffolds showing activity with in vitro and in vivo models of infections. 
  A derivation program to identify a developmental candidate within the shortest 
  possible time has been fully established.</p>
<p>As an extension of its anti-bacterial program, PLIVA has licensed-in a novel 
  anti-fungal compound (PLD-118) from Bayer AG, Germany. This compound has demonstrated 
  excellent efficacy against the most common systemic fungal infections as well 
  as excellent tolerability and pharmacokinetic properties in various pre-clinical 
  models. PLD-118 would represent the first novel, orally available compound class 
  for the treatment of infections caused by the Candida yeast since the introduction 
  of the azoles in the 1970s.The project has a novel mode of action and has strong 
  potential to solve azole resistance problems. </p>
1	<p><b>Researching the Fight Against Infection</b></p>
2	<p>PLIVA is working on becoming a leader in anti-infectives research. As such,
3	current in-house activities are focused predominantly on anti-bacterials; the
4	largest segment of anti-infectives, and in this area, PLIVA has a long tradition
5	and much expertise.</p>
6	<p>With its internationally acknowledged insight into macrolide chemistry, as
7	evidenced by its discovery of Azithromycin, PLIVA has entered into a strategic
8	co-operation with GlaxoWellcome (with the merger of SmithKline and Glaxo a novel
9	Joint Operating Committee is currently being set up) to identify a novel macrolide
10	antibiotic for world-wide development and marketing. The goal of this venture
11	is to identify a macrolide with improved efficacy, particularly against resistant
12	strains of bacteria. The program is currently keeping pace with its ambitious
13	plans and efforts are being focused on fine-tuning the derivation process in
14	order to enter the development phase within the next year.</p>
15	<p align="center"><img src="p/OKrnd_ljudi_7.jpg" width="300" height="202"></p>
16	<p>The goal of a second program within this area is to find a novel anti-bacterial
17	compound class showing no cross-resistance with current antibiotics. In cooperation
18	with Althexis, Boston, USA, a company with leading expertise in structure-based
19	drug design and crystallography, researchers from both companies have identified
20	two novel scaffolds showing activity with in vitro and in vivo models of infections.
21	A derivation program to identify a developmental candidate within the shortest
22	possible time has been fully established.</p>
23	<p>As an extension of its anti-bacterial program, PLIVA has licensed-in a novel
24	anti-fungal compound (PLD-118) from Bayer AG, Germany. This compound has demonstrated
25	excellent efficacy against the most common systemic fungal infections as well
26	as excellent tolerability and pharmacokinetic properties in various pre-clinical
27	models. PLD-118 would represent the first novel, orally available compound class
28	for the treatment of infections caused by the Candida yeast since the introduction
29	of the azoles in the 1970s.The project has a novel mode of action and has strong
30	potential to solve azole resistance problems. </p>